Biological Products, (No Diagnostic Substances) Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Biological Products, (No Diagnostic Substances)
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Share Price |
Shares Traded |
Shares Owned |
Own chg |
Value Traded |
1d ret |
1w ret |
1m ret |
6m ret |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2018-04-18 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.45 | +1,000 | 700,842 | 0% | +$1,450 | ||||||
| D | 2018-04-17 | COOL | Polarityte, Inc. | Dyer Jeffrey Hansen | Dir | P - Purchase | $16.57 | +3,000 | 26,522 | +13% | +$49,710 | |||||
| DM | 2018-04-17 | ONCE | Spark Therapeutics, Inc. | Furey John | COO | S - Sale+OE | $82.52 | -13,277 | 0 | -100% | -$1,095,683 | |||||
2018-04-16 | RGNX | Regenxbio Inc. | Vasista Vittal | CFO | S - Sale | $37.56 | -5,000 | 152,283 | -3% | -$187,797 | ||||||
| D | 2018-04-16 | SGMO | Sangamo Therapeutics, Inc | Yi Kathy | SVP, CFO | S - Sale+OE | $19.83 | -5,000 | 7,250 | -41% | -$99,144 | |||||
| D | 2018-04-13 | SGMO | Sangamo Therapeutics, Inc | Herberts Curt A. III | Sr.VP, Chief Business Officer | S - Sale+OE | $20.00 | -8,163 | 14,625 | -36% | -$163,260 | |||||
2018-04-16 | CVM | Cel Sci Corp | Young Peter R | Dir | P - Purchase | $1.80 | +6,500 | 7,691 | +546% | +$11,675 | ||||||
2018-04-12 | AMGN | Amgen Inc | Harper Sean E | EVP, Research, Development | S - Sale | $172.68 | -1,525 | 56,788 | -3% | -$263,337 | ||||||
| D | 2018-04-13 | GILD | Gilead Sciences Inc | Cogan John Francis | Dir | S - Sale+OE | $75.56 | -5,833 | 52,619 | -10% | -$440,741 | |||||
| D | 2018-04-12 | ONCE | Spark Therapeutics, Inc. | Furey John | COO | S - Sale+OE | $77.51 | -20,000 | 0 | -100% | -$1,550,200 | |||||
2017-10-12 | ONCE | Spark Therapeutics, Inc. | Sigal Elliot | Dir | P - Purchase | $90.75 | +29 | 11,214 | 0% | +$2,632 | ||||||
2017-11-28 | ONCE | Spark Therapeutics, Inc. | Sigal Elliot | Dir | S - Sale | $72.43 | -29 | 11,214 | 0% | -$2,100 | ||||||
| D | 2018-04-12 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale+OE | $180.17 | -3,000 | 24,905 | -11% | -$540,508 | |||||
| D | 2018-04-12 | MATN | Mateon Therapeutics Inc | Reynolds Donald Rogers | Dir | P - Purchase | $0.00 | +250,000 | 280,000 | +833% | +$0 | |||||
| D | 2018-04-12 | MATN | Mateon Therapeutics Inc | Schwieterman William D | Pres, CEO | P - Purchase | $0.00 | +625,000 | 625,747 | >999% | +$0 | |||||
| D | 2018-04-12 | MATN | Mateon Therapeutics Inc | Loar Matthew M | CFO | P - Purchase | $0.00 | +250,000 | 300,000 | +500% | +$0 | |||||
| D | 2018-04-11 | RGNX | Regenxbio Inc. | Christmas Patrick J. | SVP, GC | S - Sale+OE | $39.00 | -10,000 | 1,141 | -90% | -$390,000 | |||||
| D | 2018-04-12 | MNTA | Momenta Pharmaceuticals Inc | Stoner Elizabeth | Dir | S - Sale+OE | $20.00 | -7,714 | 21,664 | -26% | -$154,280 | |||||
| M | 2018-04-11 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $41.87 | -8,800 | 1,010,291 | -1% | -$368,472 | |||||
| D | 2018-04-10 | MNTA | Momenta Pharmaceuticals Inc | Wheeler Craig A | Pres, CEO | S - Sale+OE | $19.00 | -43,334 | 603,204 | -7% | -$823,346 | |||||
| D | 2018-03-21 | MNTA | Momenta Pharmaceuticals Inc | Stoner Elizabeth | Dir | S - Sale+OE | $19.00 | -3,399 | 17,777 | -16% | -$64,581 | |||||
| D | 2018-04-10 | MNTA | Momenta Pharmaceuticals Inc | Stoner Elizabeth | Dir | S - Sale+OE | $19.00 | -3,399 | 19,378 | -15% | -$64,581 | |||||
| DM | 2018-04-10 | CBMG | Cellular Biomedicine Group, Inc. | Liu Wen Tao | Dir | S - Sale+OE | $20.09 | -22,444 | 213,076 | -10% | -$450,832 | |||||
2018-04-10 | VYGR | Voyager Therapeutics, Inc. | Ravina Bernard | Chief Medical Officer | S - Sale | $18.38 | -2,451 | 0 | -100% | -$45,049 | ||||||
| D | 2018-04-09 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale+OE | $50.52 | -18,832 | 687,146 | -3% | -$951,393 | |||||
| D | 2018-04-09 | RGNX | Regenxbio Inc. | Christmas Patrick J. | SVP, GC | S - Sale+OE | $34.00 | -10,000 | 1,141 | -90% | -$340,000 | |||||
| D | 2018-04-06 | SGMO | Sangamo Therapeutics, Inc | Conner Edward R. | SVP, Chief Medical Officer | S - Sale+OE | $17.41 | -5,000 | 8,125 | -38% | -$87,065 | |||||
| D | 2018-04-06 | GILD | Gilead Sciences Inc | Cogan John Francis | Dir | S - Sale+OE | $74.47 | -5,833 | 52,619 | -10% | -$434,384 | |||||
| D | 2018-04-04 | WINT | Windtree Therapeutics Inc /de/ | Lee'S Pharmaceutical Holdings Ltd | 10% | P - Purchase | $4.80 | +541,667 | 2,853,271 | +23% | +$2,600,002 | |||||
| D | 2018-04-02 | BOLD | Audentes Therapeutics, Inc. | Patterson Matthew R | Pres, CEO | S - Sale+OE | $30.01 | -700 | 171,814 | 0% | -$21,009 | |||||
| D | 2018-04-02 | GILD | Gilead Sciences Inc | Martin John C | Dir | S - Sale+OE | $73.14 | -50,000 | 3,017,762 | -2% | -$3,656,806 | |||||
| D | 2018-04-02 | EIGR | Eiger Biopharmaceuticals, Inc. | Quan Joanne | Chief Medical Officer | S - Sale+OE | $10.00 | -4,000 | 0 | -100% | -$40,000 | |||||
2018-04-02 | AVXS | Avexis, Inc. | Kaspar Brian K. | Chief Scientific Officer | S - Sale | $119.50 | -15,000 | 1,755,602 | -1% | -$1,792,440 | ||||||
| D | 2018-04-02 | AVXS | Avexis, Inc. | Knudten Andrew F. | SrVP, Manufacture, Supply Chai | S - Sale+OE | $119.49 | -2,000 | 8,800 | -19% | -$238,982 | |||||
| D | 2018-04-02 | AVXS | Avexis, Inc. | Litalien James J | SrVP, Chief Reg, Quality Offic | S - Sale+OE | $119.44 | -5,000 | 3,800 | -57% | -$597,213 | |||||
| D | 2018-04-02 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale+OE | $168.72 | -2,250 | 29,272 | -7% | -$379,608 | |||||
| D | 2018-04-02 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale+OE | $167.52 | -22,000 | 24,905 | -47% | -$3,685,387 | |||||
2018-04-03 | XLRN | Acceleron Pharma Inc | Rovaldi Christopher | SVP, Program Mgmt, Ops | S - Sale | $38.40 | -3,500 | 25,858 | -12% | -$134,395 | ||||||
2018-04-03 | XLRN | Acceleron Pharma Inc | Kumar Ravindra | SVP, Chief Scientific Officer | S - Sale | $38.41 | -1,203 | 95,935 | -1% | -$46,205 | ||||||
2018-04-03 | XLRN | Acceleron Pharma Inc | Sherman Matthew L | EVP, Chief Medical Officer | S - Sale | $38.43 | -4,600 | 77,267 | -6% | -$176,772 | ||||||
2018-04-03 | XLRN | Acceleron Pharma Inc | McLaughlin Kevin F | SVP, CFO, Treasurer | S - Sale | $38.45 | -4,000 | 43,939 | -8% | -$153,792 | ||||||
| D | 2018-04-02 | GILD | Gilead Sciences Inc | Cogan John Francis | Dir | S - Sale+OE | $74.93 | -5,833 | 52,619 | -10% | -$437,067 | |||||
| D | 2018-04-02 | SGMO | Sangamo Therapeutics, Inc | Mento Steven J | Dir | S - Sale+OE | $18.40 | -7,215 | 44,046 | -14% | -$132,758 | |||||
| D | 2018-04-02 | SGMO | Sangamo Therapeutics, Inc | Herberts Curt A. III | Sr.VP, Chief Business Officer | S - Sale+OE | $18.30 | -2,278 | 14,625 | -13% | -$41,684 | |||||
2018-04-02 | EDIT | Editas Medicine, Inc. | Bosley Katrine | Pres, CEO | S - Sale | $32.16 | -8,333 | 1,310,298 | -1% | -$267,969 | ||||||
| A | 2018-03-27 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $38.40 | -200 | 206,478 | 0% | -$7,680 | |||||
2018-03-29 | ATRA | Atara Biotherapeutics, Inc. | Clark Mitchall G. | EVP, Chief R, QA Officer | S - Sale | $40.07 | -22,400 | 133,671 | -14% | -$897,568 | ||||||
| D | 2018-03-15 | BOLD | Audentes Therapeutics, Inc. | Newman Mary | SVP, Regulatory Affairs | S - Sale+OE | $30.36 | -10,000 | 0 | -100% | -$303,627 | |||||
| D | 2017-03-29 | BOLD | Audentes Therapeutics, Inc. | Prasad Suyash | SVP, Chief Med Officer | S - Sale+OE | $30.02 | -7,800 | 0 | -100% | -$234,195 | |||||
| M | 2018-03-27 | ADAP | Adaptimmune Therapeutics Plc | Thompson Peter A. | Dir | S - Sale | $11.50 | -1,048,067 | 5,101,310 | -17% | -$12,053,730 | |||||
| M | 2018-03-27 | ADAP | Adaptimmune Therapeutics Plc | Orbimed Advisors LLC | Dir | S - Sale | $11.50 | -1,048,067 | 5,101,310 | -17% | -$12,053,730 | |||||
| M | 2018-03-08 | FENC | Fennec Pharmaceuticals Inc. | Manchester Management Pr, LLC | 10% | S - Sale | $10.61 | -914,745 | 2,916,666 | -24% | -$9,704,023 | |||||
| M | 2017-02-28 | FENC | Fennec Pharmaceuticals Inc. | Manchester Management Pr, LLC | 10% | P - Purchase | $7.28 | +79,830 | 2,323,463 | +4% | +$581,310 | |||||
| M | 2017-04-12 | FENC | Fennec Pharmaceuticals Inc. | Manchester Management Pr, LLC | 10% | S - Sale | $9.22 | -70,100 | 2,323,463 | -3% | -$646,577 | |||||
| M | 2016-08-23 | FENC | Fennec Pharmaceuticals Inc. | Manchester Management Pr, LLC | 10% | P - Purchase | $2.01 | +96,000 | 3,795,681 | +3% | +$192,640 | |||||
| M | 2016-01-27 | FENC | Fennec Pharmaceuticals Inc. | Manchester Management Pr, LLC | 10% | P - Purchase | $2.06 | +190,850 | 4,059,013 | +5% | +$392,528 | |||||
| M | 2015-12-29 | FENC | Fennec Pharmaceuticals Inc. | Manchester Management Co LLC | 10% | P - Purchase | $1.78 | +40,600 | 3,508,831 | +1% | +$72,304 | |||||
| M | 2015-05-27 | FENC | Fennec Pharmaceuticals Inc. | Manchester Management Co LLC | 10% | P - Purchase | $1.65 | +102,960 | 3,468,231 | +3% | +$170,046 | |||||
| M | 2014-12-24 | FENC | Fennec Pharmaceuticals Inc. | Manchester Management Co LLC | 10% | P - Purchase | $2.51 | +189,800 | 3,365,271 | +6% | +$475,668 | |||||
| M | 2014-08-29 | FENC | Fennec Pharmaceuticals Inc. | Manchester Management Co LLC | 10% | P - Purchase | $2.48 | +82,666 | 3,534,803 | +2% | +$205,132 | |||||
| DM | 2018-03-26 | BOLD | Audentes Therapeutics, Inc. | Prasad Suyash | SVP, Chief Med Officer | S - Sale+OE | $30.00 | -2,200 | 0 | -100% | -$66,000 | |||||
2018-03-26 | BOLD | Audentes Therapeutics, Inc. | Lange Louis G | Dir | S - Sale | $28.89 | -48,000 | 505,974 | -9% | -$1,386,937 | ||||||
| D | 2018-03-27 | ATRA | Atara Biotherapeutics, Inc. | Clark Mitchall G. | EVP, Chief R, QA Officer | S - Sale+OE | $37.87 | -100,203 | 156,071 | -39% | -$3,795,062 | |||||
| M | 2018-03-26 | CSBR | Champions Oncology, Inc. | Morris Ronnie | CEO | P - Purchase | $3.59 | +4,535 | 1,116,582 | 0% | +$16,298 | |||||
| M | 2018-03-26 | ADAP | Adaptimmune Therapeutics Plc | Viswanathan Ravi | 10% | P - Purchase | $1.92 | +6,571,164 | 79,978,672 | +9% | +$12,587,753 | |||||
| M | 2018-03-26 | ADAP | Adaptimmune Therapeutics Plc | Sonsini Peter W. | 10% | P - Purchase | $1.92 | +6,571,164 | 79,978,672 | +9% | +$12,587,753 | |||||
| M | 2018-03-26 | ADAP | Adaptimmune Therapeutics Plc | Sandell Scott D | 10% | P - Purchase | $1.92 | +6,571,164 | 79,978,672 | +9% | +$12,587,753 | |||||
| M | 2018-03-26 | ADAP | Adaptimmune Therapeutics Plc | Mott David M | Dir, 10% | P - Purchase | $1.92 | +6,571,164 | 79,978,672 | +9% | +$12,587,753 | |||||
| M | 2018-03-26 | ADAP | Adaptimmune Therapeutics Plc | Kerins Patrick J | 10% | P - Purchase | $1.92 | +6,571,164 | 79,978,672 | +9% | +$12,587,753 | |||||
| M | 2018-03-26 | ADAP | Adaptimmune Therapeutics Plc | Florence Anthony A. Jr. | 10% | P - Purchase | $1.92 | +6,571,164 | 79,978,672 | +9% | +$12,587,753 | |||||
| M | 2018-03-26 | ADAP | Adaptimmune Therapeutics Plc | Baskett Forest | 10% | P - Purchase | $1.92 | +6,571,164 | 79,978,672 | +9% | +$12,587,753 | |||||
| M | 2018-03-26 | ADAP | Adaptimmune Therapeutics Plc | Barris Peter J | 10% | P - Purchase | $1.92 | +6,571,164 | 79,978,672 | +9% | +$12,587,753 | |||||
| M | 2018-03-26 | ADAP | Adaptimmune Therapeutics Plc | Barrett M James | 10% | P - Purchase | $1.92 | +6,571,164 | 79,978,672 | +9% | +$12,587,753 | |||||
| M | 2018-03-26 | ADAP | Adaptimmune Therapeutics Plc | New Enterprise Associates 14, L.P. | 10% | P - Purchase | $1.92 | +6,571,164 | 79,978,672 | +9% | +$12,587,753 | |||||
| D | 2018-03-26 | AST | Asterias Biotherapeutics, Inc. | Mulroy Michael H. | Pres, CEO | P - Purchase | $1.76 | +2,839 | 81,541 | +4% | +$4,997 | |||||
2018-03-26 | RGNX | Regenxbio Inc. | Vasista Vittal | CFO | S - Sale | $30.00 | -5,000 | 157,283 | -3% | -$150,000 | ||||||
| M | 2018-03-26 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $38.59 | -8,800 | 1,225,769 | -1% | -$339,549 | |||||
| D | 2018-03-27 | TCON | Tracon Pharmaceuticals, Inc. | Viswanathan Ravi | 10% | P - Purchase | $2.70 | +707,964 | 3,466,003 | +26% | +$1,911,503 | |||||
| D | 2018-03-27 | TCON | Tracon Pharmaceuticals, Inc. | Sonsini Peter W. | 10% | P - Purchase | $2.70 | +707,964 | 3,466,003 | +26% | +$1,911,503 | |||||
| D | 2018-03-27 | TCON | Tracon Pharmaceuticals, Inc. | Sandell Scott D | 10% | P - Purchase | $2.70 | +707,964 | 3,466,003 | +26% | +$1,911,503 | |||||
| D | 2018-03-27 | TCON | Tracon Pharmaceuticals, Inc. | Mott David M | 10% | P - Purchase | $2.70 | +707,964 | 3,466,003 | +26% | +$1,911,503 | |||||
| D | 2018-03-27 | TCON | Tracon Pharmaceuticals, Inc. | Kerins Patrick J | 10% | P - Purchase | $2.70 | +707,964 | 3,466,003 | +26% | +$1,911,503 | |||||
| D | 2018-03-27 | TCON | Tracon Pharmaceuticals, Inc. | Florence Anthony A. Jr. | 10% | P - Purchase | $2.70 | +707,964 | 3,466,003 | +26% | +$1,911,503 | |||||
| D | 2018-03-27 | TCON | Tracon Pharmaceuticals, Inc. | Baskett Forest | 10% | P - Purchase | $2.70 | +707,964 | 3,466,003 | +26% | +$1,911,503 | |||||
| D | 2018-03-27 | TCON | Tracon Pharmaceuticals, Inc. | Barris Peter J | 10% | P - Purchase | $2.70 | +707,964 | 3,466,003 | +26% | +$1,911,503 | |||||
| D | 2018-03-27 | TCON | Tracon Pharmaceuticals, Inc. | Barrett M James | 10% | P - Purchase | $2.70 | +707,964 | 3,466,003 | +26% | +$1,911,503 | |||||
| D | 2018-03-27 | TCON | Tracon Pharmaceuticals, Inc. | New Enterprise Associates 14, L.P. | 10% | P - Purchase | $2.70 | +707,964 | 3,466,003 | +26% | +$1,911,503 | |||||
2018-03-26 | ATRA | Atara Biotherapeutics, Inc. | Haqq Christopher | EVP, R, D, Chief Scientific Of | S - Sale | $39.79 | -18,327 | 352,905 | -5% | -$729,265 | ||||||
| M | 2018-03-23 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $1.89 | +18,000 | 3,575,094 | +1% | +$33,960 | |||||
| M | 2017-06-29 | APHB | Ampliphi Biosciences Corp | Perry Michael S | Dir | P - Purchase | $0.68 | +292,592 | 411,335 | +246% | +$200,002 | |||||
| DM | 2016-06-21 | APHB | Ampliphi Biosciences Corp | Cook Jeremy Curnock | Dir | P - Purchase | $1.54 | +354,315 | 411,435 | +620% | +$545,330 | |||||
| D | 2018-03-23 | GILD | Gilead Sciences Inc | Cogan John Francis | Dir | S - Sale+OE | $75.02 | -5,833 | 52,619 | -10% | -$437,588 | |||||
2018-03-15 | LJPC | La Jolla Pharmaceutical Co | Perceptive Advisors LLC | 10% | P - Purchase | $29.50 | +700,000 | 4,313,611 | +19% | +$20,650,000 | ||||||
| M | 2018-03-22 | CSBR | Champions Oncology, Inc. | Morris Ronnie | CEO | P - Purchase | $3.50 | +700 | 1,112,047 | 0% | +$2,447 | |||||
| DM | 2018-03-22 | VYGR | Voyager Therapeutics, Inc. | Henderson Jane | SVP, CFO, Corp. Dev. | S - Sale+OE | $20.87 | -31,100 | 0 | -100% | -$649,117 | |||||
| M | 2018-03-21 | ADAP | Adaptimmune Therapeutics Plc | Viswanathan Ravi | 10% | P - Purchase | $1.91 | +1,268,508 | 73,407,508 | +2% | +$2,417,847 | |||||
| M | 2018-03-21 | ADAP | Adaptimmune Therapeutics Plc | Sonsini Peter W. | 10% | P - Purchase | $1.91 | +1,268,508 | 73,407,508 | +2% | +$2,417,847 | |||||
| M | 2018-03-21 | ADAP | Adaptimmune Therapeutics Plc | Sandell Scott D | 10% | P - Purchase | $1.91 | +1,268,508 | 73,407,508 | +2% | +$2,417,847 | |||||
| M | 2018-03-21 | ADAP | Adaptimmune Therapeutics Plc | Mott David M | Dir, 10% | P - Purchase | $1.91 | +1,268,508 | 73,407,508 | +2% | +$2,417,847 | |||||
| M | 2018-03-21 | ADAP | Adaptimmune Therapeutics Plc | Kerins Patrick J | 10% | P - Purchase | $1.91 | +1,268,508 | 73,407,508 | +2% | +$2,417,847 |
Real-time CSV? Options? Alerts? Contact us!
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |